PPT-New developments in oncological treatment for Stage 3 NSCLC

Lung SSG 22 nd May 2018 Gareth Ayre Rationale 5year OS in all stage 3 NSCLC treated with CRT only 15 Both chemo and RT shown to upregulate PDL1 Possible synergistic action when IO given with DNAdamaging treatments. Brada. . Torino. . 6 March 2015. Perspectives in lung cancer. . Stereotactic ablative radiation therapy (. SABR). in patients with inoperable NSCLC. SABR in the context of modern radiotherapy of . Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson . Cancer Center of the University of Pennsylvania. Disclosure of Conflicts of Interest. Beth . Eaby. -Sandy, MSN, CRNP, . O. CN. ®. proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. NSCLC, non-small cell lung cancer.. Lung cancer incidence and . mortality. 1. One of the most common cancers, with . 2 . million new cases. . worldwide in . 2018. The. . most common cause of cancer death, causing nearly . Posttraumatic stress disorder (PTSD) constitutes a prevalent concern among individuals with cancer, with prevalence ranging from 3% to 4% in early-stage cancer diagnosis to 35% in individuals following medical treatment,. July 22, 2023. Adjuvant immunotherapy for resectable NSCLC. Conor E. . Steuer. , MD. Associate Professor. Disclosures. Received honoraria for . ABBvie. , Merck, Bergen Bio, . Armo. , . Mirati. , Caris, Sanofi/. Kamil Konopka. Department of Oncology, University Hospital in Cracow. Lung cancer epidemiology. Most common malignancy worldwide. 14% of all new cancers are lung cancers. Lung cancer (NSCLC&SCLC) is the second most common cancer in both men and women (excluding skin cancers). . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD. Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory.